SEC Form 4 · accession 0001144204-15-010786

SANGAMO THERAPEUTICS, INC · SGMO

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owners

Other

Other

Other

Period of report

Jan 29, 2014

Accepted (ET)

Feb 18, 2015 · 9:54 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001001233

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock^F1	Jun 5, 2014	S	66,253	$14.1305	D	2,763,188	D
Common Stock^F1	Jun 5, 2014	S	48,849	$14.135	D	2,714,339	D
Common Stock^F1	Jun 6, 2014	S	9,852	$14.0718	D	2,704,487	D
Common Stock^F1	Jun 6, 2014	S	41,749	$14.13	D	2,662,738	D
Common Stock^F1	Jun 6, 2014	S	83,500	$14.40	D	2,579,238	D
Common Stock^F1	Jun 9, 2014	S	60,955	$15.4985	D	2,518,283	D
Common Stock^F1	Jun 9, 2014	S	22,545	$15.50	D	2,495,738	D
Common Stock^F1	Jun 16, 2014	S	1,838	$16.3541	D	2,493,900	D
Common Stock^F1	Jun 16, 2014	S	3,695	$16.5231	D	2,490,205	D
Common Stock^F1	Jun 16, 2014	S	137,171	$16.5235	D	2,353,034	D
Common Stock^F1	Jun 16, 2014	S	107,796	$16.595	D	2,245,238	D
Common Stock^F1	Jul 1, 2014	S	33,080	$15.955	D	2,212,158	D
Common Stock^F1	Jul 1, 2014	S	49,620	$16.0461	D	2,162,538	D
Common Stock^F1	Jul 17, 2014	P	37,215	$12.2588	A	2,199,753	D
Common Stock^F1	Jul 24, 2014	S	124,050	$12.2792	D	2,075,703	D
Common Stock^F1	Jul 25, 2014	S	47,429	$12.3121	D	2,028,274	D
Common Stock^F1	Jul 28, 2014	S	24,810	$12.10	D	2,003,464	D
Common Stock^F1	Jul 28, 2014	S	35,271	$12.114	D	1,968,193	D
Common Stock^F1	Jul 29, 2014	S	1,407	$12.4122	D	1,966,786	D
Common Stock^F1	Jul 30, 2014	S	20,592	$12.35	D	1,946,194	D
Common Stock^F1	Jul 30, 2014	S	57,890	$12.36	D	1,888,304	D
Common Stock^F1	Jul 30, 2014	S	31,108	$12.594	D	1,857,196	D
Common Stock^F1,F2	Aug 1, 2014	S	27,770	$12.8232	D	1,829,426	D

No Table II lines on this filing.

F1The reported securities are owned by RA Capital Healthcare Fund, L.P. (the "Fund"). RA Capital Management, LLC (the "Adviser") is the general partner of the Fund, and Peter Kolchinsky is the sole manager of the Adviser. The Adviser and Mr. Kolchinsky disclaim beneficial ownership of the reported securities in reliance on Rule 16a-1(a)(1)(v) and (vii), respectively, and therefore disclaim any obligation to report ownership of the reported securities other than on behalf of the Fund. The filing of this Form 4 shall not be construed as an admission that either the Adviser or Mr. Kolchinsky is or was, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the beneficial owner of any of the securities reported herein. The number of shares reported in Col 5 of Table I and the number of options reported in Col 9 of Table II reflect the number of shares or options, as applicable, beneficially owned by the Fund as of the time of the last transaction reported herein.
F2On January 29, 2014, the Fund became a beneficial owner of more than ten percent of the outstanding shares the issuer's common stock and therefore became subject to Section 16 of the Securities Exchange Act of 1934. On August 1, 2014, the Fund ceased to be a beneficial owner of more than ten percent of the outstanding shares of the issuer's common stock and ceased to be subject to Section 16.